New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
Glaucoma Research Foundation Launches Treatment Accelerator with Transformative $5 Million Gift
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation is…
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
August 20, 2025 09:48 ET | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…
